Presentation and management of calcific mitral valve disease. (1st April 2020)

• Record Type: Journal Article
• Authors: Shamsudeen, Isabel; Fei, Linda Yi Ning; Burwash, Ian G.; Beauchesne, Luc; Chan, Vincent; Glineur, David; Chan, Kwan L.; Mesana, Thierry; Messika-Zeitoun, David
• Is Part Of: International journal of cardiology. Volume 304(2020)
• Page Start: 135
• Page End: 137
• Publication Date: 2020-04-01
• Subjects: Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2020.01.020
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Little is known about the prevalence, presentation and management of calcific mitral valve disease (CMVD). We identified 167 patients (80 ± 10 years; 79% women) with significant CMVD undergoing transthoracic echocardiography at our institution in 2016. Patients presented with significant co-morbidities, 47% had moderate/severe mitral stenosis, 38% had 3+/4+ mitral regurgitation and 15% had a combination of both. Fifty-eight percent were symptomatic. Most symptomatic patients were managed conservatively and incurred higher mortality and mortality/heart failure admission rates than those managed surgically. These data highlight the importance of gaining mechanistic insights into CMVD to prevent its occurrence and avoid the need for high-risk surgery, which is seldom performed in contemporary practice. Highlights: Little is know about the prevalence, presentation and management of calcific mitral valve disease (CMVD). Most patients were elderly women and presented with comorbidities and symptoms A vast majority of symptomatic patients were conservatively managed and incurred an excess mortality and morbidity compared to those who were operated on These data highlight the importance of gaining mechanistic insights into CMVD to prevent its occurrence and the need for a high-risk surgery seldom performed in real life.